The effect of specific immunotherapy on the expression of costimulatory molecules in late phase reaction of the skin in allergic patients

Clinical and Experimental Allergy

Volumn 34, Issue 12, 2004, Pages 1862-1867

  Plewako, H ^a   Arvidsson, M ^a   Oancea, I ^a   Hasseus B ^b   Dahlgren, U ^b   Rak, Sabina ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Costimulatory molecules; Immunotherapy; Late phase reaction; Skin biopsies

Indexed keywords

ALLERGEN; ALUTARD; B7 ANTIGEN; CD28 ANTIGEN; CD68 ANTIGEN; CD86 ANTIGEN; LIDOCAINE; PLACEBO; T6 ANTIGEN;

ADULT; ALLERGY; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHIL; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOLOGY; IMMUNOTHERAPY; LANGERHANS CELL; MACROPHAGE; MALE; PRIORITY JOURNAL; PROVOCATION TEST; SKIN BIOPSY; SKIN MANIFESTATION; T LYMPHOCYTE;

ADULT; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; BETULA; DESENSITIZATION, IMMUNOLOGIC; EOSINOPHILIA; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RHINITIS, ALLERGIC, SEASONAL; SKIN; SPUTUM; STATISTICS, NONPARAMETRIC;

EID: 11144291506     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.02120.x     Document Type: Article

References (33)

1. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
2. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99:450-3.
3. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6.
4. Arvidsson MB, Lowhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109:777-83.
5. Engel P, Gribben JG, Freeman GJ et al. The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B-lymphocytes is the CD86 differentiation antigen. Blood 1994; 84:1402-7.
6. Boussiotis VA, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM. Differential association of protein tyrosine kinases with the T-cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med 1996; 184:365-76.
7. Cordell JL, Falini B, Erber WN et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32:219-29.
8. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29:577-80.
9. Hittmair A, Schmid KW. Inhibition of endogenous peroxidase for the immunocytochemical demonstration of intermediate filament proteins (IFP). J Immunol Methods 1989; 116:199-205.
10. Frew AJ, Kay AB. The pattern of human late-phase skin reactions to extracts of aeroallergens. J Allergy Clin Immunol 1988; 81:1117-21.
11. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644-51.
12. Bodtger U, Poulsen LK, Jacobi HH, Mailing HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002; 57:297-305.
13. Freeman GJ, Gray GS, Gimmi CD et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 1991; 174:625-31.
14. Simon JC, Dietrich A, Mielke V et al. Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases. J Invest Dermatol 1994; 103:539-43.
15. Tamura N, Ishii N, Nakazawa M et al. Requirement of CD80 and CD86 molecules for antigen presentation by eosinophils. Scand J Immunol 1996; 44:229-38.
16. Woerly G, Roger N, Loiseau S, Dombrowicz D, Capron A, Capron M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. J Exp Med 1999; 190:487-95.
17. Austyn JM. Antigen-presenting cells. Experimental and clinical studies of dendritic cells. Am J Respir Crit Care Med 2000; 162 (Part 2):S146-50.
18. Wosinska-Becler., Modulation of cytokine production by mononuclear cells in allergic inflammation. The effects of Allergen Exposure and Anti-inflammatory agents. Thesis, Göteborg; 2003, ISBN:91-628-5819-X; paper IV.
19. Hattori H, Okano M, Yoshino T et al. Expression of costimulatory CD80/CD86-CD28/CD152 molecules in nasal mucosa of patients with perennial allergic rhinitis. Clin Exp Allergy 2001; 31:1242-9.
20. Eberlein-Konig B, Jung C, Rakoski J, Ring J. Immunohistochemical investigation of the cellular infiltrates at the sites of allergoid-induced late-phase cutaneous reactions associated with pollen allergen-specific immunotherapy. Clin Exp Allergy 1999; 29:1641-7.
21. Akdis CA, Joss A, Akdis M, Faith A, Blaser K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000; 14:1666-8.
22. Joss A, Akdis M, Faith A, Blaser K, Akdis CA. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol 2000; 30:1683-90.
23. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106.
24. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151:1224-34.
25. Willems F, Marchant A, Delville JP et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24:1007-9.
26. Schandene L, Alonso-Vega C, Willems F et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 1994; 152:4368-74.
27. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-61.
28. Nasser Shuabi SM, Ying S, Meng Q, Kay B, Ewan PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001; 31:3704-13.
29. Menzies-Gow A, Ying S, Sabroe I et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 2002; 169:2712-8.
30. Jahnz-Rozyk K, Glodzinska-Wyszogrodzka E, Rozynska-Polanska R, Paluchowska E, Zabielski LS. The effect of specific immunotherapy on serum eotaxin level in patients with pollinosis: preliminary studies. Pol Merkuriusz Lek 2001; 11:244-6.
31. Jung CM, Funk A, Rakoski J, Ring J. Immunohistochemical analysis of late local skin reactions during rush venom immunotherapy. Allergy 1997; 52:717-26.
32. Wilson DR, Irani AM, Walker SM et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001; 31:1705-13.
33. Leckie MJ, Ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000; 356:2144-8.